LUFR_FGFR2_DAC

Dr Luc FRIBOULET
luc.friboulet@gustaveroussy.fr

Request Access

Dataset ID	Description	Technology	Samples
EGAD50000000439	18 patients were biopsied at resistance to an FGFR inhibitor with tumor WES and/or WTS performed to identify resistance mechanisms to selective FGFR2 inhibitors across FGFR2-driven malignancies.	Illumina HiSeq 4000 Illumina NovaSeq 6000 NextSeq 500	63
EGAD50000002553	Here we sequenced biopsies from a patient with ALK-positive NSCLC progressing on first-line lorlatinib. This dataset contains one mRNA-seq and one Total-RNAseq. This aims to investigate the impact of the K1150dup mutation on lorlatinib progression and to explore potential therapeutic strategies to overcome resistance.	Illumina MiSeq Illumina NovaSeq 6000	2
EGAD50000002554	Here we sequenced biopsies from a patient with ALK-positive NSCLC progressing on first-line lorlatinib. This dataset contains one Exome-seq (the tumor and its normal). This aims to investigate the impact of the K1150dup mutation on lorlatinib progression and to explore potential therapeutic strategies to overcome resistance.	Illumina NovaSeq 6000	2